Esophageal cancer: The latest on chemoprevention and state of the art therapies

详细信息    查看全文

• 作者：Gregoire F. Le Bras^a ; Muhammad H. Farooq^a ; Gary W. Falk^b ; Claudia D. Andl ; Ph.D. ; ^a ; ^{Claudia.andl@ucf.edu" class="auth_mail" title="E-mail the corresponding author} (Associate Professor)
• 关键词：Esophageal cancer ; Cancer prevention ; Treatment ; Chemotherapy ; Immunotherapy
• 刊名：Pharmacological Research
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：113
• 期：part_PA
• 页码：236-244
• 全文大小：1259 K

文摘

Esophageal cancer is currently the 8th most common cancer worldwide and the 6th leading cause of cancer-related mortality. Despite remarkable advances, the mortality for those suffering from esophageal cancer remains high, with 5-year survival rates of less than 20%. In part, because most patients present with late-stage disease, long-term survival even after resection and therapy is disappointingly low. As we will discuss in this review, multiple characteristics specific to the disease stage and patient must be considered when choosing a treatment plan. This article will summarize current standard therapies, potential application of chemoprevention drugs and the promise and partial failure of personalized medicine, as well as novel treatments addressing this disease.